Which has better earnings and valuation, JANX or TLX?

Telix Pharmaceuticals has higher revenue and earnings than Janux Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Janux Therapeutics $10M 94.76 -$113.62M -$1.84 N/A Telix Pharmaceuticals $803.79M 5.01 -$7.12M N/A N/A

Is JANX or TLX more profitable?

Telix Pharmaceuticals' return on equity of 0.00% beat Janux Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Janux Therapeutics N/A -12.93% -12.23% Telix Pharmaceuticals N/A N/A N/A

Does the media prefer JANX or TLX?

In the previous week, Janux Therapeutics and Janux Therapeutics both had 4 articles in the media. Janux Therapeutics' average media sentiment score of 0.05 beat Telix Pharmaceuticals' score of -0.32 indicating that Janux Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Telix Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BEAM or JANX?

In the previous week, Beam Therapeutics had 1 more articles in the media than Janux Therapeutics. MarketBeat recorded 5 mentions for Beam Therapeutics and 4 mentions for Janux Therapeutics. Beam Therapeutics' average media sentiment score of 0.10 beat Janux Therapeutics' score of 0.05 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Janux Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is RLAY or JANX more profitable?

Janux Therapeutics' return on equity of -12.93% beat Relay Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Relay Therapeutics N/A -43.94% -40.11% Janux Therapeutics N/A -12.93% -12.23%

Does the media favor RLAY or JANX?

In the previous week, Relay Therapeutics and Relay Therapeutics both had 4 articles in the media. Janux Therapeutics' average media sentiment score of 0.05 beat Relay Therapeutics' score of -0.04 indicating that Janux Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Janux Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor OGN or JANX?

In the previous week, Janux Therapeutics had 3 more articles in the media than Organon & Co.. MarketBeat recorded 4 mentions for Janux Therapeutics and 1 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.50 beat Janux Therapeutics' score of 0.05 indicating that Organon & Co. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Janux Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is GPCR or JANX more profitable?

Janux Therapeutics' return on equity of -12.93% beat Structure Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Structure Therapeutics N/A -24.91% -23.67% Janux Therapeutics N/A -12.93% -12.23%

Does the media refer more to GPCR or JANX?

In the previous week, Janux Therapeutics had 2 more articles in the media than Structure Therapeutics. MarketBeat recorded 4 mentions for Janux Therapeutics and 2 mentions for Structure Therapeutics. Janux Therapeutics' average media sentiment score of 0.05 beat Structure Therapeutics' score of 0.00 indicating that Janux Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Janux Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Janux Therapeutics (JANX) Competitors

$15.54 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$15.54 0.00 (-0.03%)

As of 07/2/2026 07:24 PM Eastern

Compare

JANX vs. TLX, BEAM, RLAY, OGN, and GPCR

Should you buy Janux Therapeutics stock or one of its competitors? MarketBeat compares Janux Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Janux Therapeutics include Telix Pharmaceuticals (TLX), Beam Therapeutics (BEAM), Relay Therapeutics (RLAY), Organon & Co. (OGN), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry.

How does Janux Therapeutics compare to Telix Pharmaceuticals?

Janux Therapeutics (NASDAQ:JANX) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

Telix Pharmaceuticals' return on equity of 0.00% beat Janux Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-12.93%	-12.23%
Telix Pharmaceuticals	N/A	N/A	N/A

Janux Therapeutics currently has a consensus target price of $40.15, suggesting a potential upside of 158.39%. Telix Pharmaceuticals has a consensus target price of $21.13, suggesting a potential upside of 77.97%. Given Janux Therapeutics' higher possible upside, analysts plainly believe Janux Therapeutics is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.53
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

75.4% of Janux Therapeutics shares are held by institutional investors. 7.9% of Janux Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Janux Therapeutics has a beta of 2.52, meaning that its share price is 152% more volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.31, meaning that its share price is 131% less volatile than the broader market.

Telix Pharmaceuticals has higher revenue and earnings than Janux Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	94.76	-$113.62M	-$1.84	N/A
Telix Pharmaceuticals	$803.79M	5.01	-$7.12M	N/A	N/A

In the previous week, Janux Therapeutics and Janux Therapeutics both had 4 articles in the media. Janux Therapeutics' average media sentiment score of 0.05 beat Telix Pharmaceuticals' score of -0.32 indicating that Janux Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Telix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Janux Therapeutics beats Telix Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Janux Therapeutics compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Janux Therapeutics (NASDAQ:JANX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

Beam Therapeutics has a beta of 2.18, suggesting that its stock price is 118% more volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.52, suggesting that its stock price is 152% more volatile than the broader market.

In the previous week, Beam Therapeutics had 1 more articles in the media than Janux Therapeutics. MarketBeat recorded 5 mentions for Beam Therapeutics and 4 mentions for Janux Therapeutics. Beam Therapeutics' average media sentiment score of 0.10 beat Janux Therapeutics' score of 0.05 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Janux Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Beam Therapeutics presently has a consensus price target of $46.83, indicating a potential upside of 34.62%. Janux Therapeutics has a consensus price target of $40.15, indicating a potential upside of 158.39%. Given Janux Therapeutics' higher possible upside, analysts clearly believe Janux Therapeutics is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.53

Janux Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -39.66%. Janux Therapeutics' return on equity of -12.93% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
Janux Therapeutics	N/A	-12.93%	-12.23%

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by company insiders. Comparatively, 7.9% of Janux Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Beam Therapeutics has higher revenue and earnings than Janux Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	25.61	-$79.99M	-$0.68	N/A
Janux Therapeutics	$10M	94.76	-$113.62M	-$1.84	N/A

Summary

Janux Therapeutics beats Beam Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Janux Therapeutics compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Janux Therapeutics (NASDAQ:JANX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

Janux Therapeutics has lower revenue, but higher earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	232.78	-$276.48M	-$1.57	N/A
Janux Therapeutics	$10M	94.76	-$113.62M	-$1.84	N/A

Relay Therapeutics has a beta of 1.67, suggesting that its stock price is 67% more volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.52, suggesting that its stock price is 152% more volatile than the broader market.

97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by insiders. Comparatively, 7.9% of Janux Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Relay Therapeutics and Relay Therapeutics both had 4 articles in the media. Janux Therapeutics' average media sentiment score of 0.05 beat Relay Therapeutics' score of -0.04 indicating that Janux Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Janux Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Relay Therapeutics currently has a consensus price target of $23.30, indicating a potential upside of 24.93%. Janux Therapeutics has a consensus price target of $40.15, indicating a potential upside of 158.39%. Given Janux Therapeutics' higher probable upside, analysts plainly believe Janux Therapeutics is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.53

Janux Therapeutics' return on equity of -12.93% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-43.94%	-40.11%
Janux Therapeutics	N/A	-12.93%	-12.23%

Summary

Janux Therapeutics beats Relay Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Janux Therapeutics compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and Janux Therapeutics (NASDAQ:JANX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

Organon & Co. has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.52, meaning that its stock price is 152% more volatile than the broader market.

Organon & Co. has a net margin of 3.99% compared to Janux Therapeutics' net margin of 0.00%. Organon & Co.'s return on equity of 99.95% beat Janux Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.99%	99.95%	6.22%
Janux Therapeutics	N/A	-12.93%	-12.23%

Organon & Co. has higher revenue and earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.59
Janux Therapeutics	$10M	94.76	-$113.62M	-$1.84	N/A

Organon & Co. currently has a consensus price target of $11.40, indicating a potential downside of 15.96%. Janux Therapeutics has a consensus price target of $40.15, indicating a potential upside of 158.39%. Given Janux Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Janux Therapeutics is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.53

77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 1.6% of Organon & Co. shares are held by company insiders. Comparatively, 7.9% of Janux Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Janux Therapeutics had 3 more articles in the media than Organon & Co.. MarketBeat recorded 4 mentions for Janux Therapeutics and 1 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.50 beat Janux Therapeutics' score of 0.05 indicating that Organon & Co. is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Janux Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Organon & Co. beats Janux Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Janux Therapeutics compare to Structure Therapeutics?

Structure Therapeutics (NASDAQ:GPCR) and Janux Therapeutics (NASDAQ:JANX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Janux Therapeutics' return on equity of -12.93% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-24.91%	-23.67%
Janux Therapeutics	N/A	-12.93%	-12.23%

Structure Therapeutics has a beta of -1.5, meaning that its stock price is 250% less volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.52, meaning that its stock price is 152% more volatile than the broader market.

Janux Therapeutics has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A
Janux Therapeutics	$10M	94.76	-$113.62M	-$1.84	N/A

In the previous week, Janux Therapeutics had 2 more articles in the media than Structure Therapeutics. MarketBeat recorded 4 mentions for Janux Therapeutics and 2 mentions for Structure Therapeutics. Janux Therapeutics' average media sentiment score of 0.05 beat Structure Therapeutics' score of 0.00 indicating that Janux Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Janux Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by insiders. Comparatively, 7.9% of Janux Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Structure Therapeutics presently has a consensus target price of $110.55, indicating a potential upside of 106.82%. Janux Therapeutics has a consensus target price of $40.15, indicating a potential upside of 158.39%. Given Janux Therapeutics' higher probable upside, analysts plainly believe Janux Therapeutics is more favorable than Structure Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.53

Summary

Janux Therapeutics beats Structure Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Janux Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JANX vs. The Competition

Export

Metric	Janux Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$947.69M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-8.45	21.61	28.02	24.70
Price / Sales	94.76	340.19	540.37	99.46
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	0.98	8.66	10.96	6.46
Net Income	-$113.62M	$23.81M	$3.57B	$337.01M
7 Day Performance	4.02%	3.39%	2.12%	1.69%
1 Month Performance	16.32%	10.81%	5.25%	3.81%
1 Year Performance	-36.67%	62.61%	33.29%	23.90%

Janux Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JANX Janux Therapeutics	3.5262 of 5 stars	$15.54 flat	$40.15 +158.4%	-36.7%	$947.69M	$10M	N/A	30
TLX Telix Pharmaceuticals	4.5133 of 5 stars	$11.30 +6.0%	$21.13 +86.9%	-26.4%	$3.62B	$803.79M	N/A	1,184
BEAM Beam Therapeutics	1.9806 of 5 stars	$34.95 +0.4%	$46.83 +34.0%	+73.8%	$3.58B	$139.74M	N/A	510	Gap Down
RLAY Relay Therapeutics	2.7865 of 5 stars	$19.74 +6.4%	$23.30 +18.0%	+415.2%	$3.56B	$15.35M	N/A	330	News Coverage Insider Trade Gap Down
OGN Organon & Co.	2.0833 of 5 stars	$13.54 +0.3%	$11.40 -15.8%	+34.6%	$3.55B	$6.16B	14.55	10,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JANX) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Janux Therapeutics (JANX) Competitors

JANX vs. TLX, BEAM, RLAY, OGN, and GPCR

How does Janux Therapeutics compare to Telix Pharmaceuticals?

Summary

How does Janux Therapeutics compare to Beam Therapeutics?

Summary

How does Janux Therapeutics compare to Relay Therapeutics?

Summary

How does Janux Therapeutics compare to Organon & Co.?

Summary

How does Janux Therapeutics compare to Structure Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JANX vs. The Competition

Janux Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Janux Therapeutics (JANX) Competitors

JANX vs. TLX, BEAM, RLAY, OGN, and GPCR

How does Janux Therapeutics compare to Telix Pharmaceuticals?

Is JANX or TLX more profitable?

Do analysts recommend JANX or TLX?

Do institutionals and insiders hold more shares of JANX or TLX?

Which has more volatility and risk, JANX or TLX?

Which has better earnings and valuation, JANX or TLX?

Does the media prefer JANX or TLX?

Summary

How does Janux Therapeutics compare to Beam Therapeutics?

Which has more volatility and risk, BEAM or JANX?

Does the media favor BEAM or JANX?

Do analysts prefer BEAM or JANX?

Is BEAM or JANX more profitable?

Do institutionals & insiders have more ownership in BEAM or JANX?

Which has stronger earnings & valuation, BEAM or JANX?

Summary

How does Janux Therapeutics compare to Relay Therapeutics?

Which has better valuation & earnings, RLAY or JANX?

Which has more risk & volatility, RLAY or JANX?

Do institutionals and insiders have more ownership in RLAY or JANX?

Does the media favor RLAY or JANX?

Do analysts prefer RLAY or JANX?

Is RLAY or JANX more profitable?

Summary

How does Janux Therapeutics compare to Organon & Co.?

Which has more volatility & risk, OGN or JANX?

Is OGN or JANX more profitable?

Which has preferable valuation & earnings, OGN or JANX?

Do analysts recommend OGN or JANX?

Do insiders & institutionals have more ownership in OGN or JANX?

Does the media favor OGN or JANX?

Summary

How does Janux Therapeutics compare to Structure Therapeutics?

Is GPCR or JANX more profitable?

Which has more risk & volatility, GPCR or JANX?

Which has better valuation & earnings, GPCR or JANX?

Does the media refer more to GPCR or JANX?

Do institutionals and insiders have more ownership in GPCR or JANX?

Do analysts rate GPCR or JANX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JANX vs. The Competition

Janux Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools